Ritter Pharmaceuticals, Inc. Announces Closing Of $20,000,000 Initial Public Offering

LOS ANGELES--(BUSINESS WIRE)--Ritter Pharmaceuticals, Inc. (NASDAQ: RTTR), a pharmaceutical company developing novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases with its lead product, RP-G28, being developed for the treatment of lactose intolerance, today announced the closing of its previously announced initial public offering of 4,000,000 shares of its common stock at a price to the public of $5.00 per share. Ritter Pharmaceuticals, Inc. has granted the underwriters a 45-day option to purchase up to 600,000 additional shares of common stock to cover over-allotments, if any. Gross proceeds to Ritter from the offering were $20,000,000 before deducting underwriting discounts and commissions and other estimated offering expenses.

Help employers find you! Check out all the jobs and post your resume.